4SC AG
DGAP-News: 4SC AG / Key word(s): Annual Results 4SC AG: Conference call to be hosted on 20 March 2019 to present the annual report 2018 Planegg-Martinsried, Germany, 13 March 2019 - 4SC AG (4SC, FSE Prime Standard: VSC) will publish its annual report 2018 on 20 March 2019. On this day, the Management of 4SC AG will host a conference call at 3 pm CET (10 am ET) to inform about important developments in the reporting period and beyond. Investors, financial analysts, and journalists interested in participating in the conference call can access via the telephone numbers stated below. Please join the event conference 5-10 minutes prior to the start time. You will be asked to provide your name, company and location as well as the access code.
A presentation document supporting the conference call will be available earlier on the same day at 4SC's website. After the event, a replay can be accessed from there as well. - Announcement ends -
Further information About 4SC 4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises three key drug candidates in various stages of preclinical and clinical development: resminostat, domatinostat (4SC-202) and 4SC-208. 4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. 4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 46 employees as of 30 September 2018 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72). Forward-looking information Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Contact
4SC
LifeSci Advisors
13.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | 4SC AG |
| Fraunhoferstr. 22 | |
| 82152 Planegg-Martinsried | |
| Germany | |
| Phone: | +49 89 700763-0 |
| Fax: | +49 89 700763-29 |
| E-mail: | public@4sc.com |
| Internet: | www.4sc.com |
| ISIN: | DE000A14KL72 |
| WKN: | A14KL7 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |
786717 13.03.2019
